ReviewStrategic priorities for respiratory syncytial virus (RSV) vaccine development
Under a Creative Commons license
open access
Highlights
► New technologies provide hope that an RSV vaccine can finally be achieved. ► There are opportunities to facilitate the chance of achieving an RSV vaccine. ► There are 4 potential target populations. Each has unique challenges and opportunities. ► Clinical trials of vaccines are needed to translate results in the lab to a human vaccine. ► Additional disease burden data is needed to appropriately prioritize RSV vaccine research.
Keywords
Respiratory syncytial virus
Vaccines
Global health priorities
Cited by (0)
Copyright © 2013 Elsevier Ltd.